ACLX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

14.96M

-2.03%

-1.034

+18.83%

6.99M

-13.98%

-1.097

-2.88%

7.04M

-6.86%

-1.170

+24.47%

Estimates Revision

The market is revising Downward the revenue expectations for Arcellx, Inc. (ACLX) for FY2025, with the revenue forecasts being adjusted by -30.56% over the past three months. During the same period, the stock price has changed by -23.65%.

Revenue Estimates for FY2025

Revise Downward

-30.56%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.79%

In Past 3 Month

Stock Price

Go Down

-23.65%

In Past 3 Month

17 Analyst Rating

Wall Street analysts forecast ACLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACLX is 114.71 USD with a low forecast of 88.00 USD and a high forecast of 134.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

88.00

Averages

114.71

High

134.00

Current: 0.000

Low

88.00

Averages

114.71

High

134.00

UBS

Buy

initiated

$100

2026-01-07

New

Reason

UBS

Price Target

$100

2026-01-07

New

initiated

Buy

Reason

UBS assumed coverage of Arcellx (ACLX) with a Buy rating and $100 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Wells Fargo

initiated

$100

2025-12-22

Reason

Wells Fargo

Price Target

$100

2025-12-22

initiated

Reason

Wells Fargo initiated coverage of Arcellx with an Overweight rating and $100 price target.

Wells Fargo

initiated

$100

2025-12-22

Reason

Wells Fargo

Price Target

$100

2025-12-22

initiated

Reason

Wells Fargo initiated coverage of Arcellx with an Overweight rating and $100 price target. The firm views the company's anito-cel as a "future pillar" in the treatment of multiple myeloma. Anito-cel can expand and capture a majority of the BCMA CAR-T market in fourth-line multiple myeloma given its "attractive" efficacy and safety profile, the analyst tells investors in a research note. Wells expects "rapid uptake" upon launch in 2026. The firm also sees opportunities for Arcellx in CAR-T despite recent data from competitors.

Citi

Buy

maintain

$110

2025-11-24

Reason

Citi

Price Target

$110

2025-11-24

maintain

Buy

Reason

Citi believes today's weakness in Arcellx is "an overreaction to the highly preliminary" Phase 1 inMMyCAR data for Kelonia Therapeutics' KLN-1010. While the achievement of MRD-negativity is a positive early signal, the study featured just three patients and a maximum of three months' follow-up, "leaving critical questions about response durability entirely unanswered," according to the firm, which would be buyers on the weakness. Citi maintains a Buy rating and $110 price target on Arcellx shares.

Wolfe Research

Peer Perform

initiated

2025-11-17

Reason

Wolfe Research

Price Target

2025-11-17

initiated

Peer Perform

Reason

Wolfe Research initiated coverage of Arcellx with a Peer Perform rating and no price target. The firm's analyst of the FDA's FAERS data suggests Carvytki's neurotoxicity is decreasing, but the analyst says its "early to draw any conclusions."

Canaccord

John Newman

Buy

maintain

$121 -> $130

2025-11-03

Reason

Canaccord

John Newman

Price Target

$121 -> $130

2025-11-03

maintain

Buy

Reason

Canaccord analyst John Newman raised the firm's price target on Arcellx to $130 from $121 and keeps a Buy rating on the shares. The firm conducted a detailed analysis of factors limiting Legend / JnJ's CARVYKTI CART launchin Multiple Myeloma, which all suggest favorable launch conditions for Arcellx in 2026. They said based on their analysis of US CARVYKTI revenues, the first four quarters of the CARVYKTI revenue could have been about 2x higher, accounting for issues with Out Of Specification (OOS) product, slow manufacturing time, and infrastructure limitations.

Valuation Metrics

The current forward P/E ratio for Arcellx Inc (ACLX.O) is -14.65, compared to its 5-year average forward P/E of -20.82. For a more detailed relative valuation and DCF analysis to assess Arcellx Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-20.82

Current PE

-14.65

Overvalued PE

-7.37

Undervalued PE

-34.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-18.41

Current EV/EBITDA

-18.06

Overvalued EV/EBITDA

-7.75

Undervalued EV/EBITDA

-29.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

43.31

Current PS

67.27

Overvalued PS

94.34

Undervalued PS

-7.71

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ACLX News & Events

Events Timeline

No data

News

4.0

2025-12-22SeekingAlpha

Wells Fargo Upgrades Arcellx to Overweight Due to Potential of Multiple Myeloma CAR-T Asset

6.0

2025-12-22CNBC

Deutsche Bank Raises Woodward Price Target to $400, Reiterates Buy

9.0

2025-12-09Barron's

Cancer Research Boosts Confidence in These Small Biotech Companies

People Also Watch

Frequently Asked Questions

What is Arcellx Inc (ACLX) stock price today?

The current price of ACLX is 66.27 USD — it has increased 3.05 % in the last trading day.

What is Arcellx Inc (ACLX)'s business?

Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

What is the price predicton of ACLX Stock?

What is Arcellx Inc (ACLX)'s revenue for the last quarter?

Arcellx Inc revenue for the last quarter amounts to 4.95M USD, decreased -80.99 % YoY.

What is Arcellx Inc (ACLX)'s earnings per share (EPS) for the last quarter?

Arcellx Inc. EPS for the last quarter amounts to -0.99 USD, increased 106.25 % YoY.

What changes have occurred in the market's expectations for Arcellx Inc (ACLX)'s fundamentals?

How many employees does Arcellx Inc (ACLX). have?

Arcellx Inc (ACLX) has 163 emplpoyees as of January 10 2026.

What is Arcellx Inc (ACLX) market cap?

Today ACLX has the market capitalization of 3.83B USD.